CJC + IPA (Blend)

Each CJC-1295 no DAC + Ipamorelin batch released by Vertex Labs is supported by batch-level documentation and Certificate of Analysis availability following quality review. Documentation may include component verification, identity confirmation, purity assessment, fill verification, labeling review, and other analytical information relevant to the specific research batch.

Review available batch documentation through the
Vertex Labs COA database.
Additional information regarding laboratory review procedures, documentation standards, and quality controls is available on our
Testing Standards page.

CJC-1295 no DAC + Ipamorelin should be handled using established laboratory practices and appropriate internal quality procedures. Personnel should review the product label, component profile, batch-specific documentation, container condition, and applicable storage requirements before use in a controlled laboratory environment.

Keep the vial sealed until required for laboratory preparation and store the material according to the conditions specified on the product label. Laboratories should maintain appropriate handling, documentation, and material-control procedures for their research environment.

This blend is identified by its two-component formulation and labeled 10 mg total peptide content. The vial contains CJC-1295 no DAC 5 mg and Ipamorelin 5 mg, providing specific reference points for blend verification, batch documentation, and laboratory material tracking.

Researchers should verify the vial label, total fill amount, listed component profile, batch number, and corresponding analytical documentation before use. Maintaining clear blend identification and batch traceability supports consistent documentation across controlled laboratory workflows.